BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a license and supply agreement with AbbVie for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

The relationship is focused on the use of [F-18]MK-6240 as a biomarker in clinical trials of drugs being developed for the treatment of Alzheimer’s disease. “At Cerveau we are focused on enhancing access to key technologies that we believe have the potential to advance human health,” says Rick Hiatt, chief executive officer, Cerveau Technologies, Inc. “We are excited by the opportunity to work with AbbVie with the goal of expanding the availability of this novel investigational imaging agent to the broader scientific community.”

About Cerveau Technologies, Inc.

Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.